(Q36944067)

17 August 2017

1 reference

title

Cardiovascular risk in chronic obstructive pulmonary disease. (English)

1 reference

chronic obstructive pulmonary disease

17 August 2017

main subject

1 reference

1 reference

William Macnee

3

0 references

author name string

John D Maclay

series ordinal

1

1 reference

17 August 2017

David A McAllister

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

12

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

634-641

1 reference

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Hospitalizations and mortality in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Local and systemic inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Raised CRP levels mark metabolic and functional impairment in advanced COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Role of oxidative stress in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Production of reactive oxygen species by mitochondria: central role of complex III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Sleep--a new cardiovascular frontier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

Systemic oxidative stress in asthma, COPD, and smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2007.01136.X

10.1111/J.1440-1843.2007.01136.X

21 January 2018

Identifiers

DOI

1 reference

release_cqto3gj7bbgyvdazfkg52dahyy

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cqto3gj7bbgyvdazfkg52dahyy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference